cilostazol has been researched along with Recrudescence in 41 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 9.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The primary outcome is IS recurrence." | 6.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "Cilostazol was discontinued 2 days before replacement because of its antiplatelet effects." | 5.40 | Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. ( Ayabe, R; Ebata, Y; Fukui, A; Nakagawa, M; Okada, N; Shinohara, T; Takahashi, N; Yufu, K, 2014) |
| "Of the 1534 ischemic stroke patients who randomly assigned to aspirin or cilostazol treatment with best medical therapy by the PICASSO (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage) trial, 1240 with baseline mini-mental state examination (MMSE) scores were analysed retrospectively." | 5.34 | Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. ( Hong, KS; Kang, DW; Kwon, HS; Kwon, SU; Lee, D; Lee, EJ; Lee, JS; Lee, MH; Lim, JS; Oh, MS; Yu, KH; Yu, S, 2020) |
| "Cilostazol has been reported to control neointimal proliferation after stenting." | 5.31 | Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT). ( Awata, N; Kobayashi, T; Otsuji, S; Sakurai, M; Takeda, Y; Tsuchikane, E, 2002) |
| "Cilostazol improves clinical endovascular therapy outcomes for femoropopliteal (FP) lesions in patients with symptomatic peripheral arterial disease, but whether it also has clinical benefits for patients after drug-eluting stent implantation remains unclear." | 5.24 | Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. ( Iida, O; Kawasaki, D; Matoba, S; Nanto, S; Soga, Y; Takahara, M; Yokoi, H; Zen, K, 2017) |
| " Randomized clinical trials that compared cilostazol to aspirin and reported the endpoints of ischemic stroke, intracranial hemorrhage and any bleeding were included." | 5.12 | Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. ( Barrett, KM; Brott, TG; Ertekin-Taner, N; Gopal, N; Lin, MP; Meschia, JF; Ross, OA, 2021) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 5.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "Cilostazol seems to decrease total ISR rates in patients undergoing CAS without affecting MI/stroke/death events, both in the early and late settings." | 4.93 | Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting. ( Aggeli, K; Filis, K; Galyfos, G; Geropapas, G; Sianou, A; Sigala, F, 2016) |
| "Patients who participated in the Acute Aspirin Plus Cilostazol Dual Therapy for Non-cardiogenic Stroke Patients Within 48 Hours of Symptom Onset (ADS) trial were included in this study." | 4.31 | Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis. ( Aoki, J; Fujimoto, S; Kimura, K; Matsuzono, K; Ozawa, T, 2023) |
| "Our previous trial acute dual study (ADS) reported that dual antiplatelet therapy (DAPT) using cilostazol and aspirin did not reduce the rate of short-term neurological worsening in non-cardioembolic stroke patients." | 4.02 | Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2021) |
| " Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation." | 3.85 | Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017) |
| "Prior intracerebral hemorrhage (ICH) is associated with increased risk of ischemic stroke." | 3.01 | Prior intracerebral hemorrhage and white matter hyperintensity burden on recurrent stroke risk. ( Heo, SH; Kwon, HS; Kwon, SU; Park, JH, 2021) |
| "The primary outcome is IS recurrence." | 2.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "Secondary end points were the restenosis rate on duplex ultrasound, the rate of major adverse cardiac events, and target lesion event-free survival." | 2.78 | Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. ( Hamasaki, T; Hirano, K; Iida, O; Inoue, N; Isshiki, T; Kawasaki, D; Miyamoto, A; Miyashita, Y; Nakamura, M; Nanto, S; Shinozaki, N; Shintani, Y; Soga, Y; Suzuki, K; Tsuchiya, T; Urasawa, K; Yokoi, H; Yokoi, Y; Zen, K, 2013) |
| "Cilostazol is an antiplatelet agent that increases the intracellular concentration of cyclic adenosine monophosphate by inhibiting phosphodiesterase III; it has been shown to reduce neointimal hyperplasia in animal balloon injury models." | 2.70 | Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. ( Ayabe, S; Hara, K; Ikari, Y; Kozuma, K; Kuroda, Y; Morino, Y; Tamura, T; Tanabe, K; Yamasaki, M, 2001) |
| "Cilostazol is a potent antiplatelet agent with less serious side effects." | 2.69 | Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999) |
| "Cilostazol is a potent antiplatelet agent with antiproliferative properties." | 2.69 | Effects of cilostazol on angiographic restenosis after coronary stent placement. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, NH; Nah, DY; Park, SJ; Park, SW, 2000) |
| "A part of familial Hirschsprung disease has genetic factors in common with cerebrovascular disease." | 1.51 | A Unique Recurrent Stroke Case due to Bilateral Vertebral Artery Dissection with Familial Hirschsprung Disease. ( Abe, K; Hishikawa, N; Ohta, Y; Sasaki, R; Sato, K; Takemoto, M; Yamashita, T, 2019) |
| "Cilostazol treatment was inversely associated with restenosis for the first 2 years following EVT (P < ." | 1.42 | Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease. ( Hirano, K; Iida, O; Kawasaki, D; Nanto, K; Shintani, Y; Soga, Y; Suematsu, N; Suzuki, K; Takahara, M; Uematsu, M; Yamaoka, T, 2015) |
| "Cilostazol was discontinued 2 days before replacement because of its antiplatelet effects." | 1.40 | Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. ( Ayabe, R; Ebata, Y; Fukui, A; Nakagawa, M; Okada, N; Shinohara, T; Takahashi, N; Yufu, K, 2014) |
| "He was diagnosed as idiopathic cerebral infarction." | 1.35 | [Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs]. ( Ikegami, M; Matsuda, S; Miyashita, Y; Obara, S; Shimizu, M; Sugiyama, N; Takagi, S; Takizawa, S; Yokoyama, J, 2009) |
| "Cilostazol has been reported to control neointimal proliferation after stenting." | 1.31 | Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT). ( Awata, N; Kobayashi, T; Otsuji, S; Sakurai, M; Takeda, Y; Tsuchikane, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (17.07) | 18.2507 |
| 2000's | 8 (19.51) | 29.6817 |
| 2010's | 20 (48.78) | 24.3611 |
| 2020's | 6 (14.63) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JH | 1 |
| Kwon, SU | 3 |
| Kwon, HS | 2 |
| Heo, SH | 1 |
| Ozawa, T | 1 |
| Fujimoto, S | 2 |
| Aoki, J | 2 |
| Matsuzono, K | 1 |
| Kimura, K | 3 |
| Kim, SM | 1 |
| Jung, JM | 1 |
| Kim, BJ | 1 |
| Lee, JS | 2 |
| Lee, D | 1 |
| Lee, MH | 1 |
| Yu, S | 1 |
| Lim, JS | 1 |
| Yu, KH | 1 |
| Oh, MS | 1 |
| Hong, KS | 1 |
| Lee, EJ | 1 |
| Kang, DW | 1 |
| Hankey, GJ | 1 |
| Iguchi, Y | 1 |
| Urabe, T | 1 |
| Yamagami, H | 1 |
| Todo, K | 1 |
| Idomari, K | 1 |
| Kaneko, N | 1 |
| Iwanaga, T | 1 |
| Terasaki, T | 1 |
| Tanaka, R | 1 |
| Yamamoto, N | 1 |
| Tsujino, A | 1 |
| Nomura, K | 1 |
| Abe, K | 2 |
| Uno, M | 1 |
| Okada, Y | 1 |
| Matsuoka, H | 1 |
| Yamagata, S | 1 |
| Yamamoto, Y | 1 |
| Yonehara, T | 1 |
| Inoue, T | 1 |
| Yagita, Y | 1 |
| Lin, MP | 1 |
| Meschia, JF | 1 |
| Gopal, N | 1 |
| Barrett, KM | 1 |
| Ross, OA | 1 |
| Ertekin-Taner, N | 1 |
| Brott, TG | 1 |
| Soga, Y | 7 |
| Takahara, M | 3 |
| Iida, O | 6 |
| Yamauchi, Y | 1 |
| Hirano, K | 3 |
| Fukunaga, M | 1 |
| Zen, K | 4 |
| Suzuki, K | 5 |
| Shintani, Y | 3 |
| Miyashita, Y | 4 |
| Tsuchiya, T | 2 |
| Yamaoka, T | 2 |
| Ando, K | 2 |
| Tomoi, Y | 1 |
| Fujihara, M | 1 |
| Galyfos, G | 2 |
| Kerasidis, S | 1 |
| Kastrisios, G | 1 |
| Giannakakis, S | 1 |
| Sachmpazidis, I | 1 |
| Anastasiadou, C | 1 |
| Geropapas, G | 2 |
| Papapetrou, A | 1 |
| Papacharalampous, G | 1 |
| Maltezos, C | 1 |
| Hamasaki, T | 2 |
| Edahiro, R | 1 |
| Inoue, N | 2 |
| Yokoi, Y | 2 |
| Kawasaki, D | 4 |
| Urasawa, K | 2 |
| Aodo, K | 1 |
| Choi, PK | 1 |
| Chung, JY | 1 |
| Lee, SJ | 1 |
| Kang, HG | 1 |
| Miura, T | 1 |
| Hozawa, K | 1 |
| Doijiri, T | 1 |
| Ikeda, U | 1 |
| Kuwahara, K | 1 |
| Sato, K | 1 |
| Sasaki, R | 1 |
| Ohta, Y | 1 |
| Takemoto, M | 1 |
| Hishikawa, N | 1 |
| Yamashita, T | 1 |
| Ichihashi, S | 1 |
| Shibata, T | 1 |
| Fujimura, N | 1 |
| Nagatomi, S | 1 |
| Yamamoto, H | 1 |
| Kyuragi, R | 1 |
| Adachi, A | 1 |
| Iwakoshi, S | 1 |
| Bolstad, F | 1 |
| Saeki, K | 1 |
| Obayashi, K | 1 |
| Kichikawa, K | 1 |
| Yokoi, H | 2 |
| Miyamoto, A | 1 |
| Shinozaki, N | 1 |
| Nakamura, M | 1 |
| Isshiki, T | 1 |
| Nanto, S | 2 |
| Shinohara, T | 1 |
| Ebata, Y | 1 |
| Ayabe, R | 1 |
| Fukui, A | 1 |
| Okada, N | 1 |
| Yufu, K | 1 |
| Nakagawa, M | 1 |
| Takahashi, N | 1 |
| Nanto, K | 1 |
| Suematsu, N | 1 |
| Uematsu, M | 1 |
| Toyoda, K | 1 |
| Uchiyama, S | 1 |
| Hoshino, H | 1 |
| Origasa, H | 1 |
| Naritomi, H | 1 |
| Minematsu, K | 1 |
| Yamaguchi, T | 1 |
| Iftikhar, O | 1 |
| Oliveros, K | 1 |
| Tafur, AJ | 1 |
| Casanegra, AI | 1 |
| Sigala, F | 1 |
| Aggeli, K | 1 |
| Sianou, A | 1 |
| Filis, K | 1 |
| Wang, W | 1 |
| Zhang, L | 1 |
| Liu, W | 1 |
| Zhu, Q | 1 |
| Lan, Q | 1 |
| Zhao, J | 1 |
| Matoba, S | 1 |
| de Donato, G | 1 |
| Setacci, F | 1 |
| Mele, M | 1 |
| Giannace, G | 1 |
| Galzerano, G | 1 |
| Setacci, C | 1 |
| Sugiyama, N | 1 |
| Matsuda, S | 1 |
| Shimizu, M | 1 |
| Obara, S | 1 |
| Ikegami, M | 1 |
| Yokoyama, J | 1 |
| Takizawa, S | 1 |
| Takagi, S | 1 |
| Park, KH | 1 |
| Jeong, MH | 1 |
| Lee, MG | 1 |
| Ko, JS | 1 |
| Sim, DS | 1 |
| Yoon, NS | 1 |
| Yoon, HJ | 1 |
| Hong, YJ | 1 |
| Kim, KH | 1 |
| Park, HW | 1 |
| Kim, JH | 1 |
| Ahn, Y | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Iguchi, K | 1 |
| Noda, T | 1 |
| Kamakura, S | 1 |
| Shimizu, W | 1 |
| Tsuchikane, E | 2 |
| Kobayashi, T | 4 |
| Takeda, Y | 1 |
| Otsuji, S | 2 |
| Sakurai, M | 2 |
| Awata, N | 2 |
| Takahashi, K | 1 |
| Iijima, K | 1 |
| Nagasaki, M | 1 |
| Torii, I | 1 |
| Yamaguchi, S | 1 |
| Kobayashi, S | 1 |
| Liao, JK | 1 |
| Saitoh, S | 1 |
| Saito, T | 1 |
| Otake, A | 1 |
| Owada, T | 1 |
| Mitsugi, M | 1 |
| Hashimoto, H | 1 |
| Maruyama, Y | 1 |
| Take, S | 1 |
| Matsutani, M | 1 |
| Ueda, H | 1 |
| Hamaguchi, H | 1 |
| Konishi, H | 1 |
| Baba, Y | 1 |
| Kawaratani, H | 1 |
| Sugiura, T | 1 |
| Iwasaka, T | 1 |
| Inada, M | 1 |
| Sekiya, M | 1 |
| Funada, J | 1 |
| Watanabe, K | 1 |
| Miyagawa, M | 1 |
| Akutsu, H | 1 |
| Ishizaka, N | 1 |
| Taguchi, J | 1 |
| Kimura, Y | 1 |
| Ikari, Y | 2 |
| Aizawa, T | 1 |
| Togo, M | 1 |
| Miki, K | 1 |
| Kurokawa, K | 1 |
| Ohno, M | 1 |
| Fukuhara, A | 1 |
| Kirino, M | 1 |
| Yamasaki, K | 1 |
| Izumi, M | 1 |
| Tateyama, H | 1 |
| Park, SW | 2 |
| Lee, CW | 2 |
| Kim, HS | 2 |
| Lee, HJ | 1 |
| Park, HK | 1 |
| Hong, MK | 2 |
| Kim, JJ | 2 |
| Park, SJ | 2 |
| Yoon, Y | 1 |
| Shim, WH | 1 |
| Lee, DH | 1 |
| Pyun, WB | 1 |
| Kim, IJ | 1 |
| Jang, Y | 1 |
| Cho, SY | 1 |
| Lee, NH | 1 |
| Nah, DY | 1 |
| Kozuma, K | 1 |
| Hara, K | 1 |
| Yamasaki, M | 1 |
| Morino, Y | 1 |
| Ayabe, S | 1 |
| Kuroda, Y | 1 |
| Tanabe, K | 1 |
| Tamura, T | 1 |
| Tanabe, Y | 1 |
| Ito, E | 1 |
| Nakagawa, I | 1 |
| Yamaya, M | 1 |
| Yanai, M | 1 |
| Ohrui, T | 1 |
| Arai, H | 1 |
| Sekizawa, K | 1 |
| Sasaki, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment[NCT00912756] | Phase 4 | 200 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for cilostazol and Recrudescence
| Article | Year |
|---|---|
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Cilostazol; Female; Humans; Intracranial Hemorrhages; Ische | 2021 |
Prevention of Femoropopliteal In-Stent Restenosis With Cilostazol: A Meta-Analysis.
Topics: Cardiovascular Agents; Cilostazol; Endovascular Procedures; Femoral Artery; Humans; Odds Ratio; Peri | 2016 |
Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting.
Topics: Angioplasty; Cardiovascular Agents; Carotid Stenosis; Chi-Square Distribution; Cilostazol; Humans; M | 2016 |
Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis.
Topics: Asian People; Brain Ischemia; Cilostazol; Humans; Ischemic Attack, Transient; Network Meta-Analysis; | 2016 |
Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol.
Topics: Cardiovascular Agents; Cilostazol; Coronary Artery Disease; Coronary Restenosis; Endovascular Proced | 2017 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
15 trials available for cilostazol and Recrudescence
| Article | Year |
|---|---|
Prior intracerebral hemorrhage and white matter hyperintensity burden on recurrent stroke risk.
Topics: Aged; Cerebral Hemorrhage; Cilostazol; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; | 2021 |
Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study.
Topics: Aged; Aspirin; Cilostazol; Cognitive Dysfunction; Female; Fibrinolytic Agents; Humans; Male; Middle | 2020 |
Efficacy of CilostAzol for Below-the-Knee Artery Disease after Balloon AnGioplasty in PatiEnts with Severe Limb Ischemia (CABBAGE Trial).
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Angioplasty, Balloon; Cardiovascular Age | 2017 |
Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Cilostazol; Female; Femoral Ar | 2018 |
Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Double-Blind Metho | 2018 |
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
Topics: Aged; Aged, 80 and over; Alloys; Angioplasty; Aspirin; Cardiovascular Diseases; Cilostazol; Constric | 2013 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting S | 2017 |
Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cilostazol; Coronary Angiography; C | 1998 |
Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Calcium; Cell Division; Cilostazol; Combined Modality | 1999 |
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo | 1999 |
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp | 1999 |
Effects of cilostazol on angiographic restenosis after coronary stent placement.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Disease | 2000 |
Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation.
Topics: Cilostazol; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Ana | 2001 |
Antithrombotic therapy for prevention of pneumonia.
Topics: Aged; Cerebral Infarction; Cilostazol; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence; Pn | 2001 |
19 other studies available for cilostazol and Recrudescence
| Article | Year |
|---|---|
Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis.
Topics: Blood Pressure; Cilostazol; Humans; Ischemic Attack, Transient; Ischemic Stroke; Recurrence; Stroke | 2023 |
CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Ag | 2020 |
Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis.
Topics: Aged; Aspirin; Cilostazol; Disease Progression; Dual Anti-Platelet Therapy; Female; Humans; Japan; M | 2021 |
Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cilostazol; Databases, Factual; Endovascular Procedu | 2017 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula | 2017 |
Recurrent cerebral microbleeds with acute stroke symptoms: A case report.
Topics: Aged; Basal Ganglia Cerebrovascular Disease; Brain; Cerebral Hemorrhage; Cilostazol; Cognitive Dysfu | 2018 |
A Unique Recurrent Stroke Case due to Bilateral Vertebral Artery Dissection with Familial Hirschsprung Disease.
Topics: Adult; Aspirin; Cerebral Angiography; Cerebral Infarction; Cilostazol; Diffusion Magnetic Resonance | 2019 |
Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Constriction, Path | 2019 |
Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes.
Topics: Adult; Anti-Arrhythmia Agents; Bepridil; Cilostazol; Death, Sudden, Cardiac; Dose-Response Relations | 2014 |
Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alloys; Cardiovascular Agents; Cilostazol; Databases, | 2015 |
[Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs].
Topics: Adenosine Diphosphate; Aspirin; Blood Coagulation Tests; Cerebral Infarction; Child, Preschool; Cilo | 2009 |
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie | 2011 |
Beneficial effects of cilostazol in a patient with recurrent ventricular fibrillation associated with early repolarization syndrome.
Topics: Cilostazol; Combined Modality Therapy; Defibrillators, Implantable; Drug Therapy, Combination; Elect | 2013 |
Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT).
Topics: Aged; Atherectomy, Coronary; Blood Vessel Prosthesis Implantation; Cilostazol; Combined Modality The | 2002 |
Deterioration of vascular dementia caused by recurrent multiple small emboli from thoracic aortic atheroma.
Topics: Aged; Aorta, Thoracic; Arteriosclerosis; Cilostazol; Dementia, Vascular; Disease Progression; Emboli | 2004 |
Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cilostazol; Coronary Thrombosis; Coronary Vessels; Dog | 1993 |
Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Cilostazol; Coronary Disease; Female; Humans; Male; Middle Age | 1997 |
Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Topical; Angioplasty, Balloon; Animals; Arteria | 1999 |
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Cilos | 2001 |